For instance, in patients with PDGFRβ‐positive chordomas, the first and second‐line therapies are tyrosine‐kinase (imatinib) and epidermal growth factor receptor (EGFR) inhibitors (erlotinib), respectively.56, 57. Here, EGFR is linked to chordoma.